1. Home
  2. Category
  3. Treatment Types

Targeted Therapies

Essentials

Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors

Jean E. Boucher
Robin Sommers
CJON 2018, 22(5), 565-568 DOI: 10.1188/18.CJON.565-568
Neuroendocrine tumors (NETs), including gastroenteropancreatic NETs, or GEP-NETs, are heterogenous tumors that arise from diffuse neuroendocrine cells and other organs, such as the lung, ovary, and thyroid. Lutetium Lu 177 dotatate (Lutathera®) is a newly approved targeted therapy for patients with...
0
No votes yet
Read this Article
CNE Article

Hepatic Arterial Infusion Pump: Complications and Nursing Management Regarding Use in Patients With Colorectal Cancer

Deborah Italiano
CJON 2018, 22(3), 340-346 DOI: 10.1188/18.CJON.340-346
Background: The hepatic arterial infusion (HAI) pump is a treatment-delivery method based on the principle of targeting the tumor site directly and can be used alone or in combination with systemic chemotherapy. Objectives: The intent of this article is to serve as a resource for oncology nurses to...
0
No votes yet
Read this Article
CNE Article

Promoting Oral Therapy Adherence: Consensus Statements From the Faculty of the Melanoma Nursing Initiative on Oral Melanoma Therapies

Lisa A. Kottschade
Mollie Lehner Reed
CJON 2017, 21(4), 87-96 DOI: 10.1188/17.CJON.S4.87-96
Background: Inhibitors of BRAF and the downstream signaling protein MEK have improved outcomes for patients with BRAF-mutant advanced malignant melanoma. Despite their ease of administration, these oral therapies pose adherence challenges. Objectives: This article aims to increase awareness of...
0
No votes yet
Read this Article
CNE Article

BRAF/MEK Inhibitor Therapy: Consensus Statement From the Faculty of the Melanoma Nursing Initiative on Managing Adverse Events and Potential Drug Interactions

Maria Czupryn
Jennifer Cisneros
CJON 2017, 21(4), 11-29 DOI: 10.1188/17.CJON.S4.11-29
Background: BRAF/MEK inhibitor therapy improves outcomes in BRAF V600E- and V600K-mutated unresectable or metastatic melanoma. However, these regimens are associated with adverse events (AEs) that may lead to unnecessary drug modifications and discontinuations or potentially serious sequelae. In...
0
No votes yet
Read this Article
Online Exclusive Article

Clinical Nurse Consultant Support: Management of Patients With Melanoma Receiving Immunotherapy and Targeted Therapy

Anna J. Lomax
Theresa Nielsen
Lydia Visintin
Brent O’Carrigan
Florian Honeyball
Benjamin Shum
Robyn P.M. Saw
Catriona McNeil
CJON 2017, 21(4), E93-E98 DOI: 10.1188/17.CJON.E93-E98
Background: Targeted therapy and immunotherapy agents for advanced melanoma are associated with novel toxicities. Melanoma clinical nurse consultants (CNCs) provide multifaceted clinical care. Objectives: The objective was to evaluate the type of support, excluding clinic and inpatient care,...
0
No votes yet
Read this Article

Questions, Concerns or Requests

We're just a click away for assistance.